Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells

Allan B Dietz, Peggy A. Bulur, Michele R. Erickson, Peter J. Wettstein, Mark R Litzow, William A. Wyatt, Gordon W. Dewald, Ayalew Tefferi, V. Shane Pankratz, Stanimir Vuk-Pavlović

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The goal of this work was to optimize dendritic cell (DC) preparations obtained from patients suffering from chronic myeloid leukemia (CML) and compare them with DC prepared from normal CD14+ mononuclear cells (MNC). We studied normal DC and bcr-abl+ leukemic DC (CML-DC) yields, expression of membrane molecules, differentiation status, and ability to stimulate T cells. We isolated DC precursors from PBMC by CD14-specific immunoadsprotion and cultured them for 7 days in GM-CSF and IL-4, followed by a 3-day incubation to fully differentiate the cells. We evaluated cultures of CML-DC using RPMI 1640 medium supplemented with FBS and X-VIVO 15 medium containing human AB serum. In contrast to cells matured in RPMI 1640, virtually all cells incubated in X-VIVO 15 expressed CD83, a marker of mature DC. CML-DC and normal DC were indistinguishable in expression of CD83, resulting in the highest percentage reported so far. The yields of normal DC and CML-DC from CD14+ cells were indistinguishable. The percentage of bcr-abl+ cells in PBMC varied among patients between 65% and 97% and the final CML-DC preparations were >98% bcr-abl+ the highest purity of bcr-abl+ cells to date. Normal DC and CML-DC were equally effective in stimulating proliferation of allogeneic and autologous T cells. These techniques provide highly enriched, mature, functional CML-DC.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalJournal of Hematotherapy and Stem Cell Research
Volume9
Issue number1
DOIs
StatePublished - 2000

Fingerprint

Dendritic Cells
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
T-Lymphocytes
Granulocyte-Macrophage Colony-Stimulating Factor
Interleukin-4

ASJC Scopus subject areas

  • Hematology
  • Immunology

Cite this

Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. / Dietz, Allan B; Bulur, Peggy A.; Erickson, Michele R.; Wettstein, Peter J.; Litzow, Mark R; Wyatt, William A.; Dewald, Gordon W.; Tefferi, Ayalew; Pankratz, V. Shane; Vuk-Pavlović, Stanimir.

In: Journal of Hematotherapy and Stem Cell Research, Vol. 9, No. 1, 2000, p. 95-101.

Research output: Contribution to journalArticle

Dietz, Allan B ; Bulur, Peggy A. ; Erickson, Michele R. ; Wettstein, Peter J. ; Litzow, Mark R ; Wyatt, William A. ; Dewald, Gordon W. ; Tefferi, Ayalew ; Pankratz, V. Shane ; Vuk-Pavlović, Stanimir. / Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells. In: Journal of Hematotherapy and Stem Cell Research. 2000 ; Vol. 9, No. 1. pp. 95-101.
@article{00f0249120b643179c1396ec386f077a,
title = "Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells",
abstract = "The goal of this work was to optimize dendritic cell (DC) preparations obtained from patients suffering from chronic myeloid leukemia (CML) and compare them with DC prepared from normal CD14+ mononuclear cells (MNC). We studied normal DC and bcr-abl+ leukemic DC (CML-DC) yields, expression of membrane molecules, differentiation status, and ability to stimulate T cells. We isolated DC precursors from PBMC by CD14-specific immunoadsprotion and cultured them for 7 days in GM-CSF and IL-4, followed by a 3-day incubation to fully differentiate the cells. We evaluated cultures of CML-DC using RPMI 1640 medium supplemented with FBS and X-VIVO 15 medium containing human AB serum. In contrast to cells matured in RPMI 1640, virtually all cells incubated in X-VIVO 15 expressed CD83, a marker of mature DC. CML-DC and normal DC were indistinguishable in expression of CD83, resulting in the highest percentage reported so far. The yields of normal DC and CML-DC from CD14+ cells were indistinguishable. The percentage of bcr-abl+ cells in PBMC varied among patients between 65{\%} and 97{\%} and the final CML-DC preparations were >98{\%} bcr-abl+ the highest purity of bcr-abl+ cells to date. Normal DC and CML-DC were equally effective in stimulating proliferation of allogeneic and autologous T cells. These techniques provide highly enriched, mature, functional CML-DC.",
author = "Dietz, {Allan B} and Bulur, {Peggy A.} and Erickson, {Michele R.} and Wettstein, {Peter J.} and Litzow, {Mark R} and Wyatt, {William A.} and Dewald, {Gordon W.} and Ayalew Tefferi and Pankratz, {V. Shane} and Stanimir Vuk-Pavlović",
year = "2000",
doi = "10.1089/152581600319676",
language = "English (US)",
volume = "9",
pages = "95--101",
journal = "Stem Cells and Development",
issn = "1547-3287",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells

AU - Dietz, Allan B

AU - Bulur, Peggy A.

AU - Erickson, Michele R.

AU - Wettstein, Peter J.

AU - Litzow, Mark R

AU - Wyatt, William A.

AU - Dewald, Gordon W.

AU - Tefferi, Ayalew

AU - Pankratz, V. Shane

AU - Vuk-Pavlović, Stanimir

PY - 2000

Y1 - 2000

N2 - The goal of this work was to optimize dendritic cell (DC) preparations obtained from patients suffering from chronic myeloid leukemia (CML) and compare them with DC prepared from normal CD14+ mononuclear cells (MNC). We studied normal DC and bcr-abl+ leukemic DC (CML-DC) yields, expression of membrane molecules, differentiation status, and ability to stimulate T cells. We isolated DC precursors from PBMC by CD14-specific immunoadsprotion and cultured them for 7 days in GM-CSF and IL-4, followed by a 3-day incubation to fully differentiate the cells. We evaluated cultures of CML-DC using RPMI 1640 medium supplemented with FBS and X-VIVO 15 medium containing human AB serum. In contrast to cells matured in RPMI 1640, virtually all cells incubated in X-VIVO 15 expressed CD83, a marker of mature DC. CML-DC and normal DC were indistinguishable in expression of CD83, resulting in the highest percentage reported so far. The yields of normal DC and CML-DC from CD14+ cells were indistinguishable. The percentage of bcr-abl+ cells in PBMC varied among patients between 65% and 97% and the final CML-DC preparations were >98% bcr-abl+ the highest purity of bcr-abl+ cells to date. Normal DC and CML-DC were equally effective in stimulating proliferation of allogeneic and autologous T cells. These techniques provide highly enriched, mature, functional CML-DC.

AB - The goal of this work was to optimize dendritic cell (DC) preparations obtained from patients suffering from chronic myeloid leukemia (CML) and compare them with DC prepared from normal CD14+ mononuclear cells (MNC). We studied normal DC and bcr-abl+ leukemic DC (CML-DC) yields, expression of membrane molecules, differentiation status, and ability to stimulate T cells. We isolated DC precursors from PBMC by CD14-specific immunoadsprotion and cultured them for 7 days in GM-CSF and IL-4, followed by a 3-day incubation to fully differentiate the cells. We evaluated cultures of CML-DC using RPMI 1640 medium supplemented with FBS and X-VIVO 15 medium containing human AB serum. In contrast to cells matured in RPMI 1640, virtually all cells incubated in X-VIVO 15 expressed CD83, a marker of mature DC. CML-DC and normal DC were indistinguishable in expression of CD83, resulting in the highest percentage reported so far. The yields of normal DC and CML-DC from CD14+ cells were indistinguishable. The percentage of bcr-abl+ cells in PBMC varied among patients between 65% and 97% and the final CML-DC preparations were >98% bcr-abl+ the highest purity of bcr-abl+ cells to date. Normal DC and CML-DC were equally effective in stimulating proliferation of allogeneic and autologous T cells. These techniques provide highly enriched, mature, functional CML-DC.

UR - http://www.scopus.com/inward/record.url?scp=0034095486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034095486&partnerID=8YFLogxK

U2 - 10.1089/152581600319676

DO - 10.1089/152581600319676

M3 - Article

C2 - 10738977

AN - SCOPUS:0034095486

VL - 9

SP - 95

EP - 101

JO - Stem Cells and Development

JF - Stem Cells and Development

SN - 1547-3287

IS - 1

ER -